The Co-Development of Companion Diagnostics for New Targeted Chemotherapeutics

Pharmaceutical companies need molecular diagnostic assays for driver DNA mutations that are the targets of new chemotherapeutic agents being considered for clinical trials. The drug discovery process and the development of these molecular assays usually occur in parallel.

MutantDx has the proven ability to develop new molecular diagnostic assays to the point of defined analytical characteristics within weeks.

Dr Roger Hodkinson


MutantDx Inc.

17204 106A Avenue
Edmonton, Alberta
Canada T5S 1E6